Wegovy (Semaglutide 2.4 mg) Diarrhea When It Doesn't Go Away

How often does diarrhea happen on Wegovy 2.4 mg?

Diarrhea is listed in the Wegovy prescribing information among the most common adverse reactions. In three pooled placebo-controlled trials lasting up to 68 weeks, 30% of the 2,116 adults taking 2.4 mg weekly reported it, compared with 16% of the 1,261 adults on placebo [1]. Any gastrointestinal reaction was reported by 73% versus 47%, and severe gastrointestinal reactions by 4.1% versus 0.9% [1].

Diarrhea is common, but it is not usually the reason people stop. In the same pooled trials, 6.8% of people on Wegovy and 3.2% on placebo stopped treatment because of an adverse reaction of any kind; diarrhea accounted for 0.7% versus 0.1% [1]. In STEP 1, the 68-week trial in 1,961 adults without diabetes, gastrointestinal events led to discontinuation in 4.5% of the semaglutide 2.4 mg group versus 0.8% on placebo [2].

Other populations have their own figures. STEP 2, which enrolled 1,210 adults with type 2 diabetes, reported gastrointestinal adverse events in 63.5% on semaglutide 2.4 mg versus 34.3% on placebo [3]. In the adolescent trial, diarrhea was reported by 22% of the 133 patients on Wegovy 2.4 mg versus 19% of the 67 on placebo [1]. The label itself cautions that adverse reaction rates from different trials cannot be compared directly because trial conditions vary [1].

Why does semaglutide cause diarrhea?

Semaglutide is a GLP-1 receptor agonist, and the Wegovy label lists delayed gastric emptying among its effects [1]. The label does not say what causes diarrhea, and the trial tables record how many people reported it, not what caused each episode [1].

The label also carries a broader warning for severe gastrointestinal adverse reactions, and Wegovy is not recommended in people with severe gastroparesis [1]. Postmarketing reports listed in the label include ileus, intestinal obstruction and severe constipation with fecal impaction [1].

Dose escalation and maintenance doses

The escalation schedule steps through 0.25 mg, 0.5 mg, 1 mg and 1.7 mg at four-week intervals before reaching 2.4 mg at week 17 [1].

At the maintenance stage the current label lists two adult doses: 2.4 mg once weekly (recommended) or 1.7 mg once weekly [1].

What the label flags when GI symptoms persist

Two label safety items are worth knowing when diarrhea or other gastrointestinal symptoms continue: the kidney warning, which relates to fluid loss, and the pancreatitis warning, which concerns severe abdominal pain [1].

Volume depletion and kidney injury

The label warns about acute kidney injury due to volume depletion and says to monitor renal function in patients reporting adverse reactions that could lead to volume depletion [1]. In the Wegovy trials, acute kidney injury occurred at 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with existing kidney impairment and during dose titration, and often after gastrointestinal fluid loss [1].

Pancreatitis

The label says to observe for signs of acute pancreatitis: persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting. It says to discontinue Wegovy and start appropriate management if pancreatitis is suspected [1]. Acute pancreatitis was confirmed in 4 Wegovy-treated adults (0.2 cases per 100 patient-years) versus 1 on placebo [1].

What is not known about persistent diarrhea

The Wegovy label does not describe a treatment for diarrhea itself; its relevant warning concerns volume depletion and kidney injury [1].